Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE40.4800
- TODAY'S CHANGE (%)-0.0600 (-0.1480%)
- Bid / Lots35.0000/ 1
- Ask / Lots64.9900/ 2
- Open / Previous Close41.0500 / 40.5400
- Day Range
- 52 Week Range
- Volume300,958
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1739 | 41.05 |
| 09:50 ET | 200 | 41.36 |
| 09:52 ET | 300 | 41.63 |
| 09:56 ET | 100 | 41.515 |
| 09:57 ET | 100 | 41.63 |
| 10:01 ET | 1410 | 41.47 |
| 10:03 ET | 271 | 41.23 |
| 10:06 ET | 200 | 41.43 |
| 10:17 ET | 100 | 41.41 |
| 10:21 ET | 420 | 41.495 |
| 10:24 ET | 1035 | 41.69 |
| 10:26 ET | 100 | 41.68 |
| 10:28 ET | 300 | 41.76 |
| 10:30 ET | 1312 | 41.94 |
| 10:37 ET | 1059 | 41.885 |
| 10:39 ET | 400 | 41.9 |
| 10:42 ET | 4184 | 42.01 |
| 10:44 ET | 400 | 42.12 |
| 10:48 ET | 2723 | 41.945 |
| 10:50 ET | 2612 | 41.72 |
| 10:55 ET | 2277 | 41.59 |
| 10:57 ET | 300 | 41.58 |
| 11:00 ET | 200 | 41.67 |
| 11:04 ET | 300 | 41.6 |
| 11:06 ET | 200 | 41.575 |
| 11:08 ET | 28149 | 41.4 |
| 11:09 ET | 1124 | 41.375 |
| 11:13 ET | 200 | 41.4 |
| 11:15 ET | 1966 | 41.405 |
| 11:18 ET | 609 | 41.46 |
| 11:20 ET | 200 | 41.405 |
| 11:22 ET | 100 | 41.41 |
| 11:24 ET | 2716 | 41.38 |
| 11:26 ET | 163 | 41.415 |
| 11:27 ET | 144 | 41.415 |
| 11:29 ET | 1800 | 41.35 |
| 11:31 ET | 12183 | 41.23 |
| 11:33 ET | 1463 | 41.345 |
| 11:36 ET | 147 | 41.37 |
| 11:38 ET | 148 | 41.37 |
| 11:40 ET | 246 | 41.44 |
| 11:44 ET | 300 | 41.43 |
| 11:45 ET | 370 | 41.375 |
| 11:47 ET | 100 | 41.37 |
| 11:49 ET | 200 | 41.42 |
| 11:54 ET | 380 | 41.355 |
| 12:00 ET | 300 | 41.38 |
| 12:02 ET | 100 | 41.345 |
| 12:05 ET | 100 | 41.38 |
| 12:09 ET | 820 | 41.43 |
| 12:12 ET | 100 | 41.505 |
| 12:18 ET | 1132 | 41.47 |
| 12:20 ET | 1099 | 41.51 |
| 12:21 ET | 200 | 41.61 |
| 12:23 ET | 700 | 41.615 |
| 12:30 ET | 2068 | 41.6225 |
| 12:32 ET | 1000 | 41.665 |
| 12:34 ET | 100 | 41.645 |
| 12:36 ET | 2393 | 41.565 |
| 12:39 ET | 2405 | 41.5125 |
| 12:41 ET | 600 | 41.57 |
| 12:43 ET | 200 | 41.53 |
| 12:45 ET | 2666 | 41.5 |
| 12:48 ET | 284 | 41.5 |
| 12:50 ET | 100 | 41.375 |
| 12:54 ET | 406 | 41.36 |
| 12:56 ET | 13932 | 41.255 |
| 12:57 ET | 300 | 41.2 |
| 12:59 ET | 900 | 41.15 |
| 01:01 ET | 1785 | 41.25 |
| 01:03 ET | 3145 | 41.25 |
| 01:06 ET | 450 | 41.31 |
| 01:08 ET | 2963 | 41.25 |
| 01:12 ET | 400 | 41.23 |
| 01:17 ET | 7674 | 41.21 |
| 01:19 ET | 200 | 41.05 |
| 01:21 ET | 700 | 41.025 |
| 01:26 ET | 1494 | 41.12 |
| 01:30 ET | 100 | 41.07 |
| 01:33 ET | 508 | 41.08 |
| 01:35 ET | 1006 | 41.1 |
| 01:39 ET | 100 | 41.1 |
| 01:44 ET | 282 | 41.08 |
| 01:46 ET | 418 | 41.11 |
| 01:50 ET | 1111 | 41.25 |
| 01:51 ET | 100 | 41.3 |
| 01:55 ET | 100 | 41.255 |
| 01:57 ET | 2507 | 41.305 |
| 02:00 ET | 4352 | 41.23 |
| 02:02 ET | 100 | 41.235 |
| 02:06 ET | 400 | 41.25 |
| 02:09 ET | 7701 | 41.22 |
| 02:11 ET | 500 | 41.225 |
| 02:15 ET | 300 | 41.24 |
| 02:18 ET | 600 | 41.28 |
| 02:20 ET | 1198 | 41.28 |
| 02:22 ET | 304 | 41.27 |
| 02:24 ET | 1819 | 41.22 |
| 02:26 ET | 300 | 40.955 |
| 02:29 ET | 200 | 41.03 |
| 02:31 ET | 4336 | 41.02 |
| 02:33 ET | 218 | 41.04 |
| 02:36 ET | 900 | 41.07 |
| 02:38 ET | 400 | 41.11 |
| 02:40 ET | 200 | 41.085 |
| 02:42 ET | 100 | 41.06 |
| 02:45 ET | 400 | 41.05 |
| 02:47 ET | 100 | 41.02 |
| 02:49 ET | 100 | 41.03 |
| 02:51 ET | 200 | 41.05 |
| 02:58 ET | 2157 | 41.02 |
| 03:00 ET | 741 | 41.02 |
| 03:02 ET | 198 | 41.03 |
| 03:03 ET | 3760 | 41 |
| 03:05 ET | 308 | 41 |
| 03:07 ET | 6974 | 40.74 |
| 03:09 ET | 300 | 40.77 |
| 03:14 ET | 1100 | 40.795 |
| 03:16 ET | 900 | 40.895 |
| 03:18 ET | 820 | 40.89 |
| 03:21 ET | 411 | 40.815 |
| 03:23 ET | 100 | 40.74 |
| 03:30 ET | 100 | 40.8 |
| 03:32 ET | 108 | 40.785 |
| 03:34 ET | 100 | 40.775 |
| 03:36 ET | 108 | 40.76 |
| 03:39 ET | 100 | 40.73 |
| 03:41 ET | 900 | 40.82 |
| 03:43 ET | 3446 | 40.57 |
| 03:45 ET | 100 | 40.555 |
| 03:48 ET | 500 | 40.4901 |
| 03:50 ET | 337 | 40.58 |
| 03:52 ET | 4255 | 40.68 |
| 03:54 ET | 200 | 40.74 |
| 03:56 ET | 1829 | 40.56 |
| 03:57 ET | 4204 | 40.525 |
| 03:59 ET | 4813 | 40.48 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Iovance Biotherapeutics Inc | 3.1B | -6.0x | --- |
Apogee Therapeutics Inc | 3.0B | -30.4x | --- |
SpringWorks Therapeutics Inc | 3.0B | -8.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Biohaven Ltd | 3.1B | -6.0x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
